CD44 as a predictor in kidney cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at whether a certain protein called CD44 in kidney cancer tissue can help predict how the disease will progress. If you've had kidney cancer and your tumor tissue is available, this research might help understand your prognosis better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have kidney cancer (renal cell carcinoma).
- You must have complete medical and lab records (pathology data) for this study.
- You must not have any other type of cancer.
- You must have been followed up for at least 3 years after your kidney removal surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special computer model to predict how well your kidneys will work after surgery to remove part of a kidney (partial nephrectomy). It may help doctors plan better care for people with early-stage kidney tumors.
This study looks at whether a simple blood test can detect tiny bits of kidney cancer DNA after surgery. If successful, it could help doctors spot a return of cancer earlier than scans alone.
This study uses a computer model to analyze your CT scans and predict how long you might stay cancer-free after surgery. It aims to help doctors personalize follow-up care for clear cell kidney cancer.
This study looks at genetic features of kidney cancer by testing tumor samples. The goal is to find biomarkers—specific signs—that may help predict what kind of kidney cancer it is.
This study is checking how well a model can predict the outcomes for people with kidney cancer who have had surgery. It looks at your medical records after surgery to help doctors better understand your recovery and future risks.
This study tests whether a simple blood test that tracks tumor DNA (called ctDNA) can help predict how well immunotherapy will work for people with non-clear cell kidney cancer. If you are about to start immunotherapy for advanced disease, this study could help your doctor better understand your treatment response.
Hear when a new Renal Cell Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.